BioNexus Gene Lab Corp. (BGLC) Gross margin 2018–2025
BioNexus Gene Lab Corp. (BGLC) gross margin by fiscal year — reported gross profit divided by reported revenue.
14.6%FY2025 · since FY2018: 13.5% → 14.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 14.6% | +1.1 pp |
| FY2024 | 13.6% | -0.0 pp |
| FY2023 | 13.6% | +2.1 pp |
| FY2022 | 11.5% | -5.4 pp |
| FY2021 | 17.0% | +1.9 pp |
| FY2020 | 15.1% | -28.9 pp |
| FY2019 | 44.0% | +30.5 pp |
| FY2018 | 13.5% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice